Apollomics Inc.
APLMDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Jan 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
APL-101 Oral Capsules | Phase 2 | Solid Tumors | - | - |
APL-101 | Phase 2 | Metastatic Non Small Cell Lung Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Apollomics Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Apollomics Inc.'s (APLM) pipeline across Phase 2. Its lead program is APL-101 Oral Capsules (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Apollomics Inc.'s next FDA catalyst?→
Apollomics Inc.'s (APLM) next tracked catalyst is a Phase 2 expected January 31, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track APLM biotech catalysts?→
Add APLM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Apollomics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.